Mintorlan (Tamsulosin Hydrochloride, Solifenacin Succinate)

• Mintorlan combines tamsulosin and solifenacin to address lower urinary tract disorders.
• Benign prostatic hyperplasia (BPH): improves urine flow and reduces urinary retention.
• Overactive bladder (OAB): decreases urgency episodes and increases bladder capacity.
• Urinary urgency: alleviates frequent urges to void, helping patients regain control.

• Tamsulosin Hydrochloride selectively blocks alpha‑1 adrenergic receptors in the prostate and bladder neck, relaxing smooth‑muscle tone and facilitating urine flow. Solifenacin Succinate antagonizes muscarinic M3 receptors on the detrusor muscle, reducing involuntary contractions and expanding bladder capacity. The combined action addresses both obstruction and overactivity in the lower urinary tract.

Common Side Effects

• Dizziness or light‑headedness
• Dry mouth
• Constipation
• Headache
• Blurred vision
• Nausea

Serious or Rare Side Effects

• Priapism or prolonged erection
• Severe hypotension leading to fainting
• Acute urinary retention
• Allergic reactions such as rash or swelling
• QT interval prolongation or cardiac arrhythmia

Before initiating Mintorlan, consider the following precautions.

• Blood pressure monitoring: watch for orthostatic hypotension, especially at treatment start.
• Renal function assessment: adjust use in patients with severe renal impairment.
• Hepatic impairment: evaluate liver function, as metabolism may be affected.
• Concomitant anticholinergic load: avoid excessive anticholinergic burden.
• Urinary retention risk: monitor patients with existing retention symptoms.
• Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Mintorlan may interact with several drug classes.

Major Interactions (Avoid)

• Potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma levels.
• Other alpha‑1 blockers (e.g., prazosin, doxazosin): additive hypotensive effect.
• Additional antimuscarinic agents (e.g., oxybutynin): heightened anticholinergic side effects.

Moderate Interactions (Monitor Closely):\n- Diuretics: may exacerbate orthostatic hypotension.

• Antihypertensives: additive blood pressure lowering.
• CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy of tamsulosin.